<DOC>
	<DOCNO>NCT00117962</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed disodium may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab may also make tumor cell sensitive radiation therapy . Giving pemetrexed disodium , carboplatin , radiation therapy together cetuximab may kill tumor cell . PURPOSE : This randomized phase II trial study well give pemetrexed disodium carboplatin together radiation therapy without cetuximab work treat patient stage III non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Pemetrexed Disodium , Carboplatin , Radiation Therapy With Without Cetuximab Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall survival patient unresectable stage III non-small cell lung cancer treat pemetrexed disodium , carboplatin , thoracic radiotherapy without cetuximab . Secondary - Determine failure-free survival response rate patient treat regimen . - Correlate epidermal growth factor receptor , erbB2 , K-ras mutation survival tumor response patient treat regimen . OUTLINE : This randomize , multicenter study . - Chemoradiotherapy ( course 1-4 ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive pemetrexed disodium IV 10 minute follow carboplatin IV 30 minute day 1 , 22 , 43 , 64 . Patients also undergo thoracic radiotherapy daily day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 , 43-47 . - Arm II : Patients receive pemetrexed disodium , carboplatin , thoracic radiotherapy arm I . Patients also receive cetuximab IV 2 hour day 1 IV 1 hour day 8 , 15 , 22 , 29 , 36 , 43 . - Consolidation chemotherapy ( course 5-8 ) : Beginning 3-5 week completion chemoradiotherapy , patient receive consolidation chemotherapy comprise pemetrexed disodium alone IV 10 minute day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 100 patient ( 50 per treatment arm ) accrue study within 10-13 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Histologically cytologically document NSCLC , include squamous cell carcinoma , adenocarcinoma include bronchoalveolar cell , large cell anaplastic carcinoma ( include giant clear cell carcinoma ) 2 . Eligible Disease Stages : Inoperable IIIA Selected IIIB Patients enter must consider unresectable inoperable . Patients need mediastinoscopy . A size 2 cm great CT sufficient criterion diagnosis mediastinal lymph node ( N2 N3 ) involvement malignancy . If large mediastinal lymph node le 2 cm diameter , biopsy confirmation mediastinal nodal involvement require . 1 . The following patient eligible : Patients must M0 Patients T N2 N3 eligible Patients T3 , N1N3 disease eligible deem unresectable Patients T4 , N eligible provide T4 status determine malignant effusion Patients contralateral mediastinal disease ( N3 ) eligible gross disease encompass radiation field accordance homogeneity criterion Patients pleural effusion , transudate , cytologically negative nonbloody , eligible radiation oncologist feel tumor encompass within reasonable field radiotherapy If pleural effusion see chest CT CXR small tap , patient eligible . Patients develop new pleural effusion thoracotomy invasive thoracic procedure eligible . 2 . The follow patient NOT eligible : Patients T3 , N0 disease Patients M1 disease Patients atelectasis entire lung Patients direct invasion vertebral body Patients scalene , supraclavicular , contralateral hilar node involvement Patients exudative , bloody , cytologically malignant effusion 3 . Patients must Measurable Disease : Lesions accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥10 mm spiral CT scan . Lesions consider measurable include bone lesion , leptomeningeal disease , ascites , pleural/pericardial effusion , abdominal mass confirm followed imaging technique , cystic lesion tumor lesion situate previously irradiate area . 4 . Prior Therapy : ≥ 2 week since formal exploratory thoracotomy . No prior chemotherapy NSCLC , chest radiation therapy therapy specifically directly target EGFR pathway 5 . ECOG performance status 01 6 . Positron Emission Tomography ( PET ) use 18 fluorodeoxyglucose ( FDG ) must negative distant metastasis . PET image mandatory . 7 . Weight loss ≤ 10 % past 3 month 8 . No `` currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse . 9 . Nonpregnant nonnursing significant risk fetus/infant 10 . Age ≥ 18 year 11 . No patient uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness . 12 . No HIVpositive patient receive combination antiretroviral therapy patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy 13 . No known history hypersensitivity carboplatin , pemetrexed monoclonal antibody 14 . Required Initial Laboratory Values : 1 . Granulocytes ≥ 1,500/mcl 2 . Platelets ≥ 100,000/mcl 3 . Calculated Creatinine Clearance ≥ 45 ml/min 4 . Bilirubin &lt; 1.5 x ULN 5 . AST/ALT &lt; 3 x ULN 6 . Alkaline Phosphatase &lt; 3 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>